

**Supplementary Table 1.** Baseline sociodemographic, traditional cardiovascular risk factors and clinical characteristics of the population included in this study.

Variables	Psoriatic arthropathy (n=669)
<b><i>Sociodemographic features</i></b>	
Age at inclusion, years, mean (SD)	50.9 (11.7)
Age at the beginning of disease, years, mean (SD)	39.4 (12.7)
Sex, female, n (%)	307 (45.9)
Educational level, n (%)	
- Elementary	302 (45.1)
- Secondary / University	367 (54.9)
<b><i>Traditional CV Risk factors</i></b>	
BMI, kg/m <sup>2</sup> , mean (SD)	28.0 (4.5)
Abdominal perimeter (cm), mean (SD)	97.1 (12.9)
Hypertension, n (%)	173 (25.9)
Hypercholesterolemia, n (%)	217 (32.4)
Total cholesterol (mg/dL)	203.6 (35.3)
Triglycerides (mg/dL)	109.1 (86.3)
LDL-c (mg/dL), mean (SD)	114.5 (46.4)
HDL-c (mg/dL), mean (SD)	55.1 (15.6)
Atherogenic index, mean (SD)	3.9 (1.1)
Diabetes mellitus, n (%)	49 (7.3)
Obesity (BMI ≥30), n (%)	184 (27.5)
Smoking status, n (%)	
- Current smokers	152 (22.7)
- Past smokers	200 (29.9)
- Never smoked	317 (47.4)
<b><i>Clinical characteristics</i></b>	
Disease duration, years	9.4 [4.9-15.9]
DAS28-ESR	2.8 [2.0-3.8]
HAQ (0-3)	0.4 [0.0-0.9]
ESR, mm/1 <sup>st</sup> hour	12 [6-20]
CRP, mg/L	3.0 [1.2-7.5]
Biologic DMARDs, n (%)	284 (42.5)
Synthetic DMARDs, n (%)	495 (74.0)
NSAIDs, n (%)	312 (46.6)
GC, n (%) ever treated	115 (17.2)
Statins, n (%)	124 (18.5)
Antihypertensive Therapy	136 (20.3)

All variables are recorded at the time of inclusion in the study.

Data expressed as median [IQR] unless specified. Categorical variables are expressed as number (n) and percentages (%); Abbreviations: BMI: body mass index; CRP: C-reactive protein; CV: cardiovascular; DAS: disease activity score; DMARD: disease-modifying antirheumatic drugs; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; HDL-c: high-density lipoprotein cholesterol; GC: glucocorticoids; LDL-c: low-density lipoprotein cholesterol; NSAID: non-steroidal anti-inflammatory drugs; SD: standard deviation.

